Glioblastoma is the most aggressive and malignant form of glioma, a type of primary brain cancer. Surgery is often used to treat gliomas, along with radiation. However, since surgery and radiation fail to cure the disease, doctors may turn to additional radiation or chemotherapy. In early stages glioblastoma tumors often grow without symptoms and therefore can become quite large before symptoms arise. When the tumor becomes symptomatic, tumor growth is usually very rapid and is accompanied by altered brain function, and if left untreated the disease becomes lethal. Although primary treatment is often successful in temporarily stopping the progression of the tumor, glioblastomas almost always recur and become lethal.
Researchers at Washington University School of Medicine in St. Louis have discovered lymph node-like structures in the skull bone marrow of mice for the first time and demonstrated that they act as rapid first responders against brain cancer before distant lymph nodes get the signal that abnormal cells are present.
A joint research team led by Professor Sungsu Park of Sungkyunkwan University and Professor Sun-Ha Paek of Seoul National University College of Medicine has demonstrated for the first time that the sequence in which immune cells interact with cancer cells can critically influence the therapeutic response in glioblastoma.
Researchers have identified a critical biological difference in how glioblastoma develops in male and female laboratory models, pinpointing an immune pathway that fuels tumor growth only in females.
A comprehensive multi-cancer study from researchers at The University of Texas MD Anderson Cancer Center has revealed that cancer cells within tumors are genetically diverse, yet all carry the same core genetic changes that can be traced back to a common ancestral cell, providing a single-cell view of how tumors adapt, survive and diversify. Understanding this helps explain why some cancer cells manage to survive treatments, paving the way for more tailored diagnostic and therapeutic strategies.
Established laboratory tests mainly capture average values across many cells and show, for example, how many cancer cells survive after contact with immune cells.
A comprehensive multi-cancer study from researchers at The University of Texas MD Anderson Cancer Center has revealed that cancer cells within tumors are genetically diverse, yet all carry the same core genetic changes that can be traced back to a common ancestral cell, providing a single-cell view of how tumors adapt, survive and diversify.
Most cancer studies focus on chemical signals or stiff tumor surroundings, but the stickiness of the fluid itself has received little attention. For glioblastoma, the invasion front is about eight times more viscous than the necrotic core, creating a rising resistance that migrating cells must overcome.
Cells constantly probe their environments, searching for physical cues that guide their behavior. And yet a cell's response to its environment is always biochemical, mediated by the chemistry of its internal protein machinery.
Glioblastoma, the most common and most aggressive brain tumor type in adults, remains difficult to treat because it can infiltrate surrounding brain tissue and spread far beyond the main tumor.
Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, announces new data demonstrating the platform’s ability to also potentially develop vaccines for glioblastoma (brain cancer).
Cells are enveloped by a lipid membrane that gives them structure and provides a barrier between the cell and its environment. However, evidence has recently emerged suggesting that these membranes do more than simply provide protection - they also influence the behavior of the protein receptors embedded in them.
A research team under the direction of the Medical University of Vienna has identified a potential new method for drug development in a recently published review.
A groundbreaking study from Brown University Health researchers has identified a crucial factor that may help improve treatment for glioblastoma, one of the most aggressive and common forms of adult brain cancer.
UCLA scientists have developed advanced miniature 3D tumor organoid models that make it possible to study glioblastoma tumors in a setting that closely mirrors the human brain, shedding light on how the aggressive cancer interacts with surrounding brain cells and the immune system to become more invasive and resistant to therapy.
With a five-year survival rate of less than 5%, glioblastoma is one of the most aggressive types of brain cancer.
A new study, led by researchers at Sylvester Comprehensive Cancer Center part of the University of Miami Miller School of Medicine, captured details of glioblastoma that had never before been seen and revealed a surprise finding: Glioblastoma cells that "cluster" together with other cells of the same type are less deadly than those that disperse from these clusters.
A new study, led by researchers at Children's Hospital of Philadelphia (CHOP), identified tiny pieces of messenger RNA that are missing in pediatric high-grade glioma tumors but not in normal brain tissues.
An experimental mRNA vaccine improved the tumor-fighting benefits of immunotherapy in a mouse model study, bringing researchers one step closer to their aim of generating a universal vaccination to “wake up” the immune system against cancer.
A team of researchers from the San Raffaele-Telethon Institute for Gene Therapy (SR-TIGET, Milan), led by Nadia Coltella and Luigi Naldini, has unveiled a powerful strategy to rejuvenate the effectiveness of chimeric antigen receptor (CAR) T cell therapy against glioblastoma, one of the most lethal and treatment-resistant brain tumors.
A new study reveals the biological secret to the Zika virus's infectious success: Zika uses host cells' own "self-care" system of clearing away useless molecules to suppress the host proteins that the virus has employed to get into those cells in the first place.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.